Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAVILION: Port Delivery System With Ranibizumab in Diabetic Retinopathy
NCT04503551Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2020
- Primary completion
- Oct 2022
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in diabetic retinopathy (DR) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale at 52 weeks. Started Aug 2020; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT04503551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503551.